Journal
AMERICAN JOURNAL OF CARDIOLOGY
Volume 92, Issue 4, Pages 436-439Publisher
EXCERPTA MEDICA INC
DOI: 10.1016/S0002-9149(03)00661-1
Keywords
-
Categories
Ask authors/readers for more resources
This phase I open label, dose-escalating study shows that gene transfer of vascular endothelial growth factor-2 naked deoxyribonucleic acid by direct myocardial injection by way of thoracotomy in patients with Canadian Cardiovascular Society class 3 or 4 angina is feasible and safe. The procedure is well tolerated, with few major adverse cardiac events at I year, and without complications directly related to gene expression. In this prospective, nonblinded study, the procedure is associated with clinical improvement; however, there was no angiographic evidence of angiogenesis and there is a great potential for a sham or placebo effect in the study patients. A randomized phase III trial is underway that will help determine the efficacy of vascular endothelial growth factor-2 gene transfer in no-option patients. (C)2003 by Excerpta Medica, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available